Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jan;59(1):145-51.
doi: 10.1128/AAC.03513-14. Epub 2014 Oct 20.

LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus

Anna C Nilsson  1 , Håkan Janson  2 , Hedda Wold  3 , Anders Fugelli  3 , Karin Andersson  4 , Camilla Håkangård  4 , Pernilla Olsson  4 , Wenche Marie Olsen  3
Affiliations
Clinical Trial

LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus

Anna C Nilsson et al. Antimicrob Agents Chemother. 2015 Jan.

Abstract

Nasal decolonization has a proven effect on the prevention of severe Staphylococcus aureus infections and the control of methicillin-resistant S. aureus (MRSA). However, rising rates of resistance to antibiotics highlight the need for new substances for nasal decolonization. LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. This mechanism of action is not associated with cross-resistance and has a low propensity for development of resistance. In the present study, persistent nasal MRSA and methicillin-sensitive S. aureus (MSSA) carriers were treated for 3 days with vehicle or with 1%, 2%, or 5% LTX-109. A significant effect on nasal decolonization was observed already after 2 days of LTX-109 treatment in subjects treated with 2% or 5% LTX-109 compared to vehicle (P ≤ 0.0012 by Dunnett's test). No safety issues were noted during the 9-week follow-up period. Minimal reversible epithelial lesions were observed in the nasal cavity. The systemic exposure was very low, with a maximum concentration of drug in plasma (Cmax) at 1 to 2 h postdosing (3.72 to 11.7 ng/ml). One week after treatment initiation, LTX-109 was not detectable in any subject. Intranasal treatment of S. aureus with LTX-109 is safe and reduces the bacterial load already after a single day of treatment. Hence, LTX-109 has potential as a new and effective antimicrobial agent with a low propensity of resistance development that can prevent infections by MSSA/MRSA during hospitalization. (This study has been registered at ClinicalTrials.gov under registration no. NCT01158235.).

PubMed Disclaimer

Figures

FIG 1
FIG 1
Disposition of subjects in the study.
FIG 2
FIG 2
Nasal decolonization during days 1 to 4 and weeks 2 to 9 after treatment with vehicle or 1%, 2%, or 5% LTX-109. The mean bacterial load, analyzed as CFU/ml, with standard deviation (SD) is shown. The minimum CFU detectable is represented by a horizontal line. At days 3 and day 4 there was a statistically significant reduction in the 2% LTX-109 group (P = 0.0008 and P = 0.0180, respectively) and the 5% LTX-109 group (P = 0.0012 and P = 0.0105, respectively) compared to vehicle (Dunnett's test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5:751–762. doi:10.1016/S1473-3099(05)70295-4. - DOI - PubMed
    1. Williams RE, Jevons MP, Shooter RA, Hunter CJ, Girling JA, Griffiths JD, Taylor GW. 1959. Nasal staphylococci and sepsis in hospital patients. Br Med J 2:658–662. doi:10.1136/bmj.2.5153.658. - DOI - PMC - PubMed
    1. Kluytmans JA, Mouton JW, Ijzerman EP, Vandenbroucke-Grauls CM, Maat AW, Wagenvoort JH, Verbrugh HA. 1995. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 171:216–219. doi:10.1093/infdis/171.1.216. - DOI - PubMed
    1. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA. 2002. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346:1871–1877. doi:10.1056/NEJMoa003069. - DOI - PubMed
    1. Munoz P, Hortal J, Giannella M, Barrio JM, Rodriguez-Creixems M, Perez MJ, Rincon C, Bouza E. 2008. Nasal carriage of S. aureus increases the risk of surgical site infection after major heart surgery. J Hosp Infect 68:25–31. doi:10.1016/j.jhin.2007.08.010. - DOI - PubMed

Publication types

Substances

Associated data